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Fabrication and in vitro evaluation of subgingival strips of 
calcium alginate for controlled delivery of ofloxacin and 
metronidazole
Katakam Prakash, Bahlul Z Awen, Chandu B Rao, Adiki S Kumari.
Faculty of Pharmacy, 7th of April University, Al-Zawia (Libya).
RESUMEN
Objetivos: Elaborar  y evaluar  tiras subgingivales combinadas compuestas por Ofloxacino y 
metronidazol in vitro  con alginato de calcio biodegradable
Métodos: las tiras se prepararon utilizando el método  de evaporación del disolvente. Se usó una 
concentración del 10% de CaCl2 para la gelificación.de las tiras.
Resultados: el grosor de las tiras se encuentra dentro de las recomendaciones (>320 µm). In vitro, la 
liberación de la droga siguió una cinética bifásica que fue suficiente para alcanzar la CMI e inhibir el 
crecimiento de microorganismos durante 5 días. La “tasa de liberación de la droga” es inversamente 
proporcional a la concentración de polímero de la formulación. La liberación de la “droga” fue por 
difusión y en segunda fase por disolución
Discusión: Las preparaciones OM1 y OM2 que contienen un 90 y un 75% de polímero respectivamente, 
podrían ser empleadas en liberación controlada durante cinco días en infecciones sublinguales. 
Siendo el alginato cálcico biodegradable una buena elección como polímero retardante
PALABRAS CLAVE: Biodegradable, Liberador de droga bifásico, Alginato de calcio, Liberación 
controlada, Tiras subgingivales
ABSTRACT 
Aim: Subgingival strips of combined ofloxacin (OFX) and metronidazole (MET) were fabricated and 
evaluated in vitro using biodegradable calcium alginate. 
Methods: Strips of drug:polymer (10:90, 25:75, 50:50 and 75:25) were prepared using solvent casting 
method. A 10%w/v CaCl2  solution was used for gelation of the strips. 
Results: The thickness of strips were at par of recommended thickness (<320 µm). In vitro release 
of drugs followed a biphasic kinetics which was sufficient to maintain the minimum inhibitory 
concentrations (MIC) to inhibit the growth of the microorganisms for 5 days. The rate of drug release 
was inversely proportional to polymer concentration in the formulations. The drug release was by 
diffusion in second phase of dissolution. 
Conclusions: The formulations OM1 and OM2 which contain 90 and 75%w/w of polymer could be 
employed for controlled delivery of combined OFX and MET for 5 days in subgingival infections. 
Calcium alginate, being a biodegradable is a good choice as drug retarding polymer.
KEY WORDS: Biodegradable, Polymer Biphasic drug release, Calcium Alginate, Controlled Release, 
Subgingival strips.
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Table 1. Composition of cast subgingival strips
INTRODUCTION
Periodontitis is a tooth destructive disease that affects 
about 15% of the population. Apart from scaling and 
planing, systemic antibiotic therapy is employed in treating 
periodontitis1. Systemic antimicrobial therapy requires 
high doses over a prolonged period to achieve required 
concentrations in the sulcular fluid which results in adverse 
effects2. Development of local delivery devices which can 
be placed directly into the periodontal pocket promise a 
relief to the patient. These devices can maintain extremely 
high local concentrations of drug for period of up to one to 
two weeks. Several implantable devices like fibers3, strips4,5 
and gels6 were studied. Various biodegradable polymers 
such as poly(glycolide-co-dl-lactide)7, polyester poly(β-
caprolactone)8, glycerol monooleate9 and cross linked 
atelocollagen10 were employed as drug carriers.
The disadvantages of synthetic polymers insist the 
researcher to explore new avenues in drug delivery systems 
using natural biopolymers. Sodium alginate is natural 
hydrophilic, biodegradable polymer and has controllable 
porosity, bioadhesivity and biocompatibility11,12. Calcium 
alginate is prepared by displacing sodium ion from 
sodium alginate. It has been used as controlled release 
drug delivery device13-15 and employed to treat orthodontic 
constructions in periodontal diseases16 and bone marrow 
implants17. In our previous work for the first time we have 
reported the design and evaluation of calcium alginate 
subgingival films of cephalexin18.
Ofloxacin (OFX) is an oral synthetic intermediate spectrum 
fluoroquinolone antibacterial agent active against enteric 
bacteria and other eubacteria. It is a broad-spectrum 
antibiotic that is active against both Gram-positive and 
Gram-negative bacteria19,20. It is also effective against 
Streptococcus mutans and Porphyromonas gingivalis that 
are present in periodontal infections21 and was investigated 
for its local delivery to periodontal pockets22.  Resorbable 
hydoxypropylcellulose based devices for the delivery of 
ofloxacin was reported earlier22,23. Metronidazole is an oral 
synthetic nitroimidazole antimicrobial agent, active against 
anaerobic bacteria and against protozoa24,25. Metronidazole 
(MET) is bactericidal against many gram-positive and most 
gram-negative anaerobic bacteria. It is also effective against 
Porphyromonas gingivalis26 that are present in periodontal 
infections with MIC of 0.125 µg/ml and was investigated 
for its local delivery to periodontal pockets27,28. Literature 
survey revealed that subgingival strips of calcium alginate 
for controlled delivery of ofloxacin and metronidazole was 
not reported except our earlier work for the first time18. 
The aim of the present investigation was to fabricate and 
evaluate the controlled release subgingival strips containing 
combintion of ofloxacin and metronidazole using calcium 
alginate as biodegradable carrier.
MATERIALS AND METHODS
Materials
Ofloxacin and Metronidazole were gratis samples from 
Alkem Laboratories, Mumbai, India. Sodium alginate (200-
600 cps and 120 mesh size), anhydrous CaCl2, propylene 
glycol, monobasic potassium phosphate were purchased 
from BDH Chemicals Ltd., London. 
Spectrophotometric method for the estimation of OFX 
and MET
The spectrophotometric method was developed to estimate 
OFX and MET simultaneously in pH 7.5 phosphate buffer. 
A stock solution containing 100μg/mL of each drug was 
prepared and scanned using UV-Visible spectrophotometer 
(Jenway 6505, UK, No. 2177). The λmax and absorbance 
were measured. Further serial dilutions were made to 
obtain linearity range of concentration of OFX and MET. 
Standard graph was constructed; the regression equation 
and correlation coefficients (r) were calculated using MS 
Excel software.
Preparation of subgingival strips
The subgingival strips of sodium alginate were prepared 
using solvent casting technique on leveled glass plate and 
glass tubes18 providing a surface area of 3.142 cm2. The 
formulations containing drug:polymer ratios of 10:90, 
25:75, 50:50 and 75:25 were designed as summarized in 
Table 1. Sodium alginate was dissolved in deionized water 
in a glass bottle (5mL) by stirring for 1 h using a magnetic 
stirrer (Heidolph MR 3002, RPM 500, Germany) with 1 cm 
Teflon® coated stirrer bar. Propylene glycol (10%w/w) 
Formulation Drug: Polymer Drug (mg) Polymer (mg) Propylene glycol(mg) Water (ml) Druga in strip (mg)
OM1 10:90 20 180 18 2 1.11
OM2 25:75 50 150 15 2 2.775
OM3 50:50 100 100 10 2 5.55
OM4 75:25 150 50 5 2 8.325
aTheoretical amount of ofloxacin and metronidazole discretely present in each strip of size 0.5×0.7 cm.
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was added to the bottle as a plasticizer. Then OFX and 
MET were added to get required concentrations as above. 
After complete mixing a 2 ml solution was poured into 
glass cylinder fixed on the fabricated glass plate placed on 
a horizontal plane. The glass plate was loosely covered so 
that the solvent (distilled water) was allowed to evaporate 
slowly at 24°C for 24-48 h. After complete evaporation of 
solvent, cast strips were collected. Then the strips were 
placed separately in food grade aluminum foil cups of 2 
cm diameter containing 0.5ml solution of 10%w/v CaCl2 so 
that they are immersed completely. The cups are left aside 
at room temperature for complete drying. Finally the dried 
calcium alginate strips were cut into pieces of 0.5×0.7 cm 
(area of 0.35 cm2) size and wrapped in an aluminium foil 
and stored in a desiccator at room temperature in a dark 
place until further studies.
Evaluation of subgingival strips
Various properties such as size, thickness, weight variation, 
folding fortitude, percentage moisture loss and content 
uniformity were determined on the formulations. The 
thickness was measured at 6 locations on the strips using 
micrometer (Mitutoyo, Japan) and the average value was 
noted. Individual weights of three strips were measured on 
top loading electronic balance (Sartorius BP 310S, Germany) 
and the mean weight was measured. Folding fortitude was 
measured by repeatedly folding the strip of 1×1 cm size 
at same place until it broke. Percentage moisture loss was 
determined by placing the strip in a desiccator containing 
anhydrous CaCl2. After 72 h, the strips were weighed and 
the percentage moisture loss was calculated using the 
following formula.
Drug content estimation
Three strips were powdered using mortar and 10 ml pH 
7.5 phosphate buffer was added to dissolve the drug. The 
solution was filtered through Whatman No. 44 filter paper 
and the drugs contents were determined at λmax of 288 
and 321 nm for OFX and MET respectively after suitable 
dilution using UV/Vis spectrophotometer. The extract of 
strips without drugs was used as blank.
Differential scanning calorimetry (DSC)
The main principle involved in determination of the 
enthalpy of caloric process by measuring the heat flow 
between samples and reference with linear or isothermal 
heating or cooling and calibration of the heat capacity 
with fusion heat standards. DSC study of pure OFX, MET, 
calcium alginate free strip, and prepared formulation 
(OM2) was performed using a JEOL JSM 5200 DSC to 
determine the drug excipient compatibility. The analysis 
was conducted at a rate 50oC min-1 from 0o to 350oC 
temperature range under nitrogen flow of 25 ml min-1.
2.7. In vitro drug release studies
The strips (0.5×0.7 cm size) were placed separately in 5 ml 
glass vials with polyethylene cap containing 1 ml of pH 
7.5 phosphate buffer. As the pH of crevicular fluids vary 
from 7.5-8.5 depending on pathological condition29, the 
pH 7.5 was selected in the present study. The vials were 
capped and placed in an incubator to maintain body 
temperature of 37oC during dissolution study. A 1mL of 
the buffer containing dissolved drug from the vial was 
withdrawn using a micropipette (Gilson 462046C, France) 
at time intervals of 1, 2, 4, 8, 12, 16, 24, 36, 48, 72, 96 and 
120 h. The sample was collected into a 10mL volumetric 
flask and an equal volume (1mL) of fresh buffer was 
replaced immediately into the vial after the withdrawal of 
the sample. The absorbance was measured after suitable 
dilutions at λmax 288 for OFX and 321 nm for MET using 
standard graphs. The dissolution kinetics was calculated 
using Microsoft Excel Software.
Stability studies
Stability studies were conducted by placing triplicates of 
the strips of size 0.5×0.7mm wrapped in aluminium foils 
and placing them at room temperature (25±5oC), in oven 
(40±2oC) and in refrigerator (4±2oC) over a period of three 
months. The strips were observed for physical changes like 
colour, texture, and drug content at periodical intervals of 
10 days each. The change in absorbance of OFX and MET 
was also studied during the study.
RESULTS
A UV method for simultaneous determination of OFX and 
MET in pH 7.5 phosphate buffer was developed. The λmax 
were obtained as 288 for OFX and 321 nm for MET. From 
the standard graph the regression equations and correlation 
coefficients (r) were calculated and found to be y=0.047x–
0.228 (r=0.998) and y=0.087x–0.022 (r=0.999) for OFX and 
MET respectively.  The linearity was obtained as 5–50 µg for 
OFX and as 0.5–20 µg for MET. The equipment necessary 
for the present investigation was successfully fabricated 
and employed for casting of sodium alginate subgingival 
strips with the help of a mould made of glass cylinder. All 
the prepared strips were found to be uniform in thickness 
with rough to smooth surface as the polymer concentration 
increased. The strips containing 25% w/w of polymer have 
shown granular surface. Upon treatment of the strips with 
a 10%w/v CaCl2 solution resulted in slightly wrinkled strip 
structure upon drying to the formulations containing 90% 
of the polymer. All the formulations resulted in gelation 
after treatment with CaCl2 solution.
The strip properties such as size, thickness, weight 
variation, folding fortitude, percentage moisture loss and 
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Table 2. Evaluation data of ofloxacin and metronidazole subgingival strips
Figure 1. Thermograms of (a) calcium alginate 
free strip, (b) ofloxacin, (c) metronidazole and (d) 
formulation OM2
Batch No.a Thickness (µm) (n=6)
Weight (mg) 
(n=3)
Drug Content (mg) 
(n=3)
% Drug 
Content 
Folding 
fortitudeb
Moisture 
Loss (%)
OM1 127±0.6 15.19±0.35
0.419±0.31c 
0.810±0.81d
37.75c 
72.97d
31±5 19±5.2
OM2 171±0.9 17.42±0.63
0.592±0.97c 
1.500±1.04d
21.33c 
54.05d
23±6 17±4.6 
OM3 224±1.1 21.06±0.77
1.994±0.69c 
6.560±0.28d
35.93c 
76.35d
18±5 12±3.4
OM4 289±1.8 19.47±0.94
2.544±0.74c 
7.301±0.29d
30.56c 
87.70d
11±3 9±1.5 
All the values are mean with ± standard deviation; aEach strip has size of 0.5×0.7 cm; bnumber of times folded; cdrug content of ofloxacin; ddrug 
content of metronidazole
content uniformity were determined and summarized 
in Table 2. The thickness of strips varied from 127±0.6 to 
289±1.8 μm. The thickness increased proportionally to 
drugs concentration in the strips. The average weight of the 
strips was found to be between 15.19±0.35 and 21.06±0.77 
mg for the strip size of 0.5×0.7 cm and area of 0.35 cm2. The 
folding fortitude of the strips was directly proportional 
to the polymer concentration. The percent moisture loss 
after drying of the strips was found to be between 9±1.5 
and 19±5.2% and increased as drug concentration was 
increased. The percentage of OFX and MET content ranged 
from 21.33–37.75 and 54.05–87.70% respectively. DSC 
thermograms of calcium alginate free strip (a), ofloxacin 
(b), metronidazole (c) and controlled release subgingival 
formulation containing drug:polymer of 25:75 (OM2) (d) 
were shown in Figure 1. The DSC results demonstrated 
a sharp endothermic peak for OFX and MET at 278.2 
and 252.1°C correspondingly. Similar endothermic peaks 
were observed in the controlled release subgingival strip 
(OM2).
In vitro drug release studies performed using pH 7.5 
phosphate buffer which simulates gingival crevicular 
fluid29. All the strips showed an initial burst release for the 
first 8 h, followed by controlled release of OFX and MET 
(>0.25 µg/ml and >0.125 µg/ml respectively) up to 120 h. 
The rate of drugs released was inversely proportional to 
polymer concentration in the formulations. The Figures 
2 - 5 summarize the release patterns and kinetics of OFX 
and MET from alginate subgingival strips. A phase of 
sharp release of OFX and MET was observed within 8 
h followed by a steady release plateau phase from all 
the formulations. The log% of drug remaining vs time 
plots resulted in regression curves as shown in Figures 
4 and 5. The regression equations of OFX obtained were; 
y = –0.015x + 1.172, y = –0.010x + 1.212, y = –0.010x + 1.509 and 
y = –0.012x + 1.477 from the formulations OM1, OM2, OM3 
and OM4 respectively. Similar regression equations were 
found for MET such as, y = –0.011x + 1.271, y = –0.009x + 1.431, 
y = –0.011x + 1.270 and y = –0.009x + 1.407; where x is time 
in h and y is log% of drug released from the formulations. 
The dissolution kinetic parameters are summarized in 
Table 3. Higher OFX and MET release of >97.80 and 97.27% 
respectively, were found from all the strips after 120 h. The 
formulations followed first order release kinetics with K1 
values for OFX and MET obtained in a range of 0.02303–
0.034545 and 0.020727–0.025333 respectively.  A similar 
observation of half-lives were found between 20.06–30.09 
and 27.35–33.43 h for OFX and MET correspondingly. The 
low values of correlation coefficient (r) of <0.9165 and 
<0.9252 for OFX and MET respectively were obtained. 
From the Higuchi equation values of <0.789338 for OFX 
and <0.751076 for MET were found. The strips have shown 
to have integrity even after 5 days of dissolution studies. 
Ars Pharm. 2012; 53(3): 26-33.
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Figure 2. Cumulative % of ofloxacin remaining vs 
time from subgingival strips of formulations; OM1 
(-♦-), OM2 (-■-), OM3 (-▲-) and OM4 (-×-).
Figure 4. Log % of ofloxacin remaining vs time from 
subgingival strips of formulations; OM1 (-♦-), OM2 
(-■-), OM3 (-▲-) and OM4 (-×-).
Table 3. Evaluation data of ofloxacin and metronidazole subgingival strips
Formulation First order rate constant (K1) h-1
Half life 
T50 (h)
Correlation 
coefficient (r)
Higuchi 
constant
Drug released 
after 120 h (%)
OM1a 0.034545 20.06 0.8938 0.789338 97.80±5.7
OM2a 0.02303 30.09 0.8111 0.698072 99.32±4.1
OM3a 0.02303 30.09 0.9549 0.572701 98.75±4.8
OM4a 0.027636 25.07 0.9165 0.570397 99.80±3.6
OM1b 0.025333 27.35 0.8643 0.751076 97.41±2.9
OM2b 0.020727 33.43 0.9252 0.674419 97.27±5.3
OM3b 0.025333 27.35 0.8349 0.62623 98.75±4.6
OM4b 0.020727 33.43 0.8385 0.611265 98.95±2.5
adrug content of ofloxacin; bdrug content of metronidazole.
Figure 3. Cumulative % of metronidazole remaining 
vs time from subgingival strips of formulations; OM1 
(-♦-), OM2 (-■-), OM3 (-▲-) and OM4 (-×-).
Figure 5. Log % of metronidazole remaining vs time 
from subgingival strips of formulations; OM1 (-♦-), 
OM2 (-■-), OM3 (-▲-) and OM4 (-×-).
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During the stability studies the strips did not show any 
significant change in physical properties. The drug content 
did not alter by more than 3.7% for all the formulations. 
Stability studies indicated that there was no change in 
physical properties and drug content throughout the 
period of observation for all the formulations.
DISCUSSION
The developed UV method for simultaneous determination 
of OFX and MET in pH 7.5 phosphate buffer has indicated 
good correlation and linearity for both the drugs. Strips 
can be prepared using solvent casting technique. As drug 
concentration was increased the smoothness of the films 
decreased due to their presence in the form of dispersion 
as crystalline form. The decreased folding fortitude of the 
films with increased drug concentration might be due to 
decreased binding of polymer molecules with the presence 
of drugs in the strips. Propylene glycol used as plasticizer 
contributed for the strips to have improved flexibility. The 
formulation OM1 has resulted in slightly wrinkled strips 
after treatment with CaCl2 solution. This may be due to the 
fact that the formulations containing high concentration of 
polymer form hydrogel when wetted and then upon drying 
might have resulted in formation of folds. The observed 
gelation of all the formulations after treatment with CaCl2 
solution indicated that the resultant strips were converted 
into calcium alginate.
The thickness of strips was found well below the 
recommended thickness of <320 µm of the subgingival 
strips which facilitates them to be inserted into the 
subgingival space for delivery of drug30. The thickness 
increased proportionally to drugs concentration in the 
strips because of aggregation of drug particles. The folding 
fortitude of the strips was directly proportional to the 
polymer concentration which is essential for structural 
integrity and robustness of the prepared strips. The high 
moisture content (18±5.9%) found in the formulation 
OM1 may be due to high polymer concentration which is 
hydrophilic in nature and contributes for more absorption 
of moisture. All the formulations contained less drugs 
content than expected theoretical values which might have 
resulted from the loss of drugs during treatment of sodium 
alginate strips with CaCl2 solution. It was also found that 
there was more loss of OFX during gelation process which 
is due to its high aqueous solubility compared to that of 
MET. The DSC results have shown no variation in the 
endothermic peaks of OFX and MET in pure form and in 
formulation indicate that the drugs present inside the strips 
as crystalline form with no significant physical or chemical 
interaction between drugs and polymer.
For invitro drug release studies pH 7.5 phosphate buffer was 
used to simulates gingival crevicular fluid29. The biphasic 
drug release pattern showing initial burst release followed 
by controlled release of OFX and MET (>0.25 µg/ml and 
>0.125 µg/ml respectively) up to 120 h showed that it is 
sufficient to inhibit the growth of the microorganisms26,31. 
From second day onwards the calculated OFX release was 
more than 40 times of its MIC and that of MET was more 
than 160 times of its MIC. The faster drug release from the 
formulations containing low polymer concentration might 
be due to the formation of more pores and channels in the 
strips by the drug itself. A phase of sharp release of OFX 
and MET was observed within 8 h followed by a steady 
release plateau phase from all the formulations. This may 
be due to the sudden release of drug from the surface of the 
strips into dissolution medium followed by a slow release 
from the inner layers of the strip by diffusion mechanism.
The OFX and MET release from the strips showed that 
calcium alginate has the ability to retard the drugs upto 
120 h. The observed low K1 values might have resulted 
from the biphasic drug release pattern of the drug from the 
strips. A similar observation of half-lives for OFX and MET 
correspondingly due to the same reason. The low values of 
correlation coefficient (r) of <0.9165 and <0.9252 for OFX 
and MET respectively were justified due to biphasic drug 
release with initial sharp followed by plateau phase. The 
formulations did not fit into Higuchi equation because of 
low values of <0.789338 and <0.751076 which correspond 
to OFX and MET. This indicates that the drugs release from 
strips might be due to only diffusion in the second phase 
of dissolution process. The integrity of the strips even after 
5 days of dissolution studies indicates that the formed 
calcium alginate gel was strong enough to be placed in 
the subgingival cavity for sufficient period of time for 
controlled release of the drugs. The strips were stable 
during stability period which indicate that there was no 
change in physical properties and drug content throughout 
the period of observation for all the formulations.
Local subgingival controlled delivery of antibiotics 
using biodegradable polymers is of recent interest to 
formulation scientist. The present investigation shows 
that the formulation OM1 and OM2 which contain 90 and 
75%w/w of polymer could be employed for controlled 
delivery of ofloxacin and metronidazole together for 5 
days in subgingival infections. Calcium alginate, being 
a biodegradable polymer is a good choice in the present 
study. It has other advantages like biocompatibility, 
natural origin, hydrogel-property and bioadhesivity which 
culminate to make this polymer a judicious choice as drug 
carrier for controlled release subgingival delivery strips.
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